Search Results

There are 6272 results for: content related to: Quality of care indicators for gout management

  1. Allopurinol for chronic gout

    Intervention Review

    The Cochrane Library

    Rakhi Seth, Alison SR Kydd, Rachelle Buchbinder, Claire Bombardier and Christopher J Edwards

    Published Online : 14 OCT 2014, DOI: 10.1002/14651858.CD006077.pub3

  2. Uricosuric medications for chronic gout

    Intervention Review

    The Cochrane Library

    Alison SR Kydd, Rakhi Seth, Rachelle Buchbinder, Christopher J Edwards and Claire Bombardier

    Published Online : 14 NOV 2014, DOI: 10.1002/14651858.CD010457.pub2

  3. You have free access to this content
    2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

    Arthritis Care & Research

    Volume 64, Issue 10, October 2012, Pages: 1431–1446, Dinesh Khanna, John D. Fitzgerald, Puja P. Khanna, Sangmee Bae, Manjit K. Singh, Tuhina Neogi, Michael H. Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Fernando Perez-Ruiz, Will Taylor, Frédéric Lioté, Hyon Choi, Jasvinder A. Singh, Nicola Dalbeth, Sanford Kaplan, Vandana Niyyar, Danielle Jones, Steven A. Yarows, Blake Roessler, Gail Kerr, Charles King, Gerald Levy, Daniel E. Furst, N. Lawrence Edwards, Brian Mandell, H. Ralph Schumacher, Mark Robbins, Neil Wenger and Robert Terkeltaub

    Article first published online : 28 SEP 2012, DOI: 10.1002/acr.21772

  4. Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events

    Seminars in Dialysis

    Volume 20, Issue 5, September/October 2007, Pages: 391–395, Nicola Dalbeth and Lisa Stamp

    Article first published online : 17 APR 2007, DOI: 10.1111/j.1525-139X.2007.00270.x

  5. You have free access to this content
    The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

    Arthritis & Rheumatism

    Volume 29, Issue 1, January 1986, Pages: 82–87, Joyce Z. Singer and Stanley L. Wallace

    Article first published online : 29 NOV 2005, DOI: 10.1002/art.1780290111

  6. You have free access to this content
    Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative

    International Journal of Rheumatic Diseases

    Volume 18, Issue 3, March 2015, Pages: 341–351, Scott W. Graf, Samuel L. Whittle, Mihir D. Wechalekar, John H. Y. Moi, Claire Barrett, Catherine L. Hill, Geoff Littlejohn, Nora Lynch, Gabor Major, Andrew L. Taylor, Rachelle Buchbinder and Jane Zochling

    Article first published online : 17 APR 2015, DOI: 10.1111/1756-185X.12557

  7. You have free access to this content
    Efficacy and safety of desensitization to allopurinol following cutaneous reactions

    Arthritis & Rheumatism

    Volume 44, Issue 1, January 2001, Pages: 231–238, Adel G. Fam, Shelly M. Dunne, John Iazzetta and Thomas W. Paton

    Article first published online : 25 JAN 2001, DOI: 10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7

  8. REVIEW: Management of gout: beyond allopurinol

    Internal Medicine Journal

    Volume 40, Issue 8, August 2010, Pages: 545–553, N. W. McGill

    Article first published online : 18 AUG 2010, DOI: 10.1111/j.1445-5994.2010.02293.x

  9. Gout

    Evidence-Based Rheumatology

    Naomi Schlesinger, Ralph Schumacher, Pages: 65–95, 2009

    Published Online : 3 AUG 2009, DOI: 10.1002/9781444315844.ch5

  10. You have free access to this content
    Supplement: 21st rheumatism review

    Arthritis & Rheumatism

    Volume 17, Issue 5, September/October 1974, Pages: 651–910,

    Article first published online : 22 NOV 2005, DOI: 10.1002/art.1780170522

  11. You have free access to this content
    Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

    Arthritis & Rheumatism

    Volume 52, Issue 3, March 2005, Pages: 916–923, Michael A. Becker, H. Ralph Schumacher Jr., Robert L. Wortmann, Patricia A. MacDonald, William A. Palo, Denise Eustace, Laurent Vernillet and Nancy Joseph-Ridge

    Article first published online : 4 MAR 2005, DOI: 10.1002/art.20935

  12. You have free access to this content
    Understanding the dose–response relationship of allopurinol: predicting the optimal dosage

    British Journal of Clinical Pharmacology

    Volume 76, Issue 6, December 2013, Pages: 932–938, Garry G. Graham, Diluk R. W. Kannangara, Sophie L. Stocker, Ian Portek, Kevin D. Pile, Praveen L. Indraratna, Indira Datta, Kenneth M. Williams and Richard O. Day

    Article first published online : 20 NOV 2013, DOI: 10.1111/bcp.12126

  13. Emerging therapies in the long-term management of hyperuricaemia and gout

    Internal Medicine Journal

    Volume 37, Issue 4, April 2007, Pages: 258–266, L. K. Stamp, 1,2 J. L. O’Donnell and 2 P. T Chapman 1,2

    Article first published online : 27 MAR 2007, DOI: 10.1111/j.1445-5994.2007.01315.x

  14. Urate-Lowering Therapy for Gout: Focus on Febuxostat

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 6, June 2010, Pages: 594–608, Bryan L. Love, Robert Barrons, Angie Veverka and K. Matthew Snider

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.30.6.594

  15. Nineteenth rheumatism review. Part-III

    Arthritis & Rheumatism

    Volume 13, Issue 5, September/October 1970, Pages: 617–694,

    Article first published online : 24 FEB 2008, DOI: 10.1002/art.1780130503

  16. Update on gout and hyperuricemia

    International Journal of Clinical Practice

    Volume 64, Issue 3, February 2010, Pages: 371–377, J. F. Baker and H. Ralph Schumacher

    Article first published online : 11 NOV 2009, DOI: 10.1111/j.1742-1241.2009.02188.x

  17. You have free access to this content
    Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

    Arthritis & Rheumatism

    Volume 63, Issue 2, February 2011, Pages: 412–421, Lisa K. Stamp, John L. O'Donnell, Mei Zhang, Jill James, Christopher Frampton, Murray L. Barclay and Peter T. Chapman

    Article first published online : 28 JAN 2011, DOI: 10.1002/art.30119

  18. ALLOPURINOL HYPERSENSITIVITY: A POTENTIALLY LIFE THREATENING REACTION

    Australasian Journal of Dermatology

    Volume 25, Issue 2, August 1984, Pages: 59–67, Carl Vinciullo

    Article first published online : 28 JUN 2007, DOI: 10.1111/j.1440-0960.1984.tb00628.x

  19. You have free access to this content
    Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal

    Arthritis & Rheumatism

    Volume 64, Issue 2, February 2012, Pages: 327–338, Tuhina Neogi, Jacob George, Sushma Rekhraj, Allan D. Struthers, Hyon Choi and Robert A. Terkeltaub

    Article first published online : 27 JAN 2012, DOI: 10.1002/art.33369

  20. You have free access to this content
    The pharmacokinetics of oxypurinol in people with gout

    British Journal of Clinical Pharmacology

    Volume 74, Issue 3, September 2012, Pages: 477–489, Sophie L. Stocker, Andrew J. McLachlan, Radojka M. Savic, Carl M. Kirkpatrick, Garry G. Graham, Kenneth M. Williams and Richard O. Day

    Article first published online : 6 AUG 2012, DOI: 10.1111/j.1365-2125.2012.04207.x